Cyplasin Biomedical Ltd Announces Japanese Patent for its Antitumor Protein
"It is gratifying to receive the approval of our patent application since it was obtained after many years of careful in-depth-analysis by the Japanese Patent Office. It describes our intellectual property for the cytotoxic Cyplasin to be used as an anticancer substance, especially valuable in one of the most important economies worldwide. Together with corresponding US and European patents Cyplasin Biomedical Ltd relies now on a solid intellectual property portfolio allowing it to proceed successfully in the rapid development of Cyplasin," said Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.
Cyplasin-SC TM has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC TM is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as an anti-cancer therapeutic product. United States and European Patents have been issued to the Company covering the Cyplasin-SC TM protein.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.